Aclidinium Bromide/Formoterol Fumarate Dihydrate

阿地溴铵/富马酸福莫特罗

Report date: 2026/05/26 20:00:28

Base Information

Drug NameAclidinium Bromide/Formoterol Fumarate Dihydrate
Drug Alias NameAclidinium/Formoterol Fumarate Dihydrate富马酸福莫特罗/阿地溴铵阿地溴铵福莫特罗Aclidinium Bromide/Formoterol fumarateFormoterol Fumarate Dihydrate/Aclidinium Bromide +[11] 
ClassificationSmall molecules
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonistsBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptorMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructive
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryEU
Original Approved Date2014/11/19
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsYes Formoterol FumarateAclidinium Bromide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesCovis PharmaCovis Pharma BvIndustrias Farmaceuticas Almirall Sa +[6] 
Inactive CompaniesAstrazeneca Plc
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsN/A

Other Information

ATC CodeR03AL05
Related LinksN/A